- Osimertinib - a new oral third-generation EGFR TKI2017 | Publication without faculty affiliation
- Lasting effect of pazopanib in first-line treatment of renal cell carcinoma2015 | First Faculty of Medicine
- Treatment of chronic myeloid leukemia in adults in 20102010 | Faculty of Medicine in Hradec Králové
- Case studies of patients treated with osimertinib2019 | Second Faculty of Medicine
- Cardiotoxicity of anti-cancer drugs in experimental settings2017 | Faculty of Medicine in Hradec Králové
- Kidney cancer. What is the next step after failure of treatment with angiogenesis inhibitors?2010 | Second Faculty of Medicine
- Targeted therapy in pulmonary medicine2016 | First Faculty of Medicine
- Profile of the drug Xalkori2014 | Faculty of Medicine in Pilsen
- The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies2018 | Faculty of Medicine in Hradec Králové
- Perspectives in the treatment of less common mutations in patients with non-small cell lung carcinoma2023 | Publication without faculty affiliation
- Sorafenib2007 | First Faculty of Medicine
- Tagrisso (osimertinib)2016 | Publication without faculty affiliation
- New drug profile - gefitinib (AstraZeneca)2005 | Faculty of Medicine in Pilsen
- Gefitinib2005 | Faculty of Medicine in Pilsen
- New drug profile - gefitinib (AstraZeneca)2005 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Gefitinib2005 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Pazopanibe2011 | First Faculty of Medicine
- Strategy of treatment in metastatic non-small cell lung cancer with driver mutations2016 | Faculty of Medicine in Pilsen
- Targeted therapeutics and their role in the treatment of internal diseases2013 | First Faculty of Medicine
- Treatment decisions in chronic myeloid leukemia in the view of BCR-ABL1 mutations in practice2010 | Faculty of Medicine in Hradec Králové
- Afatinib - clinical practice experience2018 | Second Faculty of Medicine
- Basic principles of the treatment of hematological malignancies2013 | First Faculty of Medicine
- What brings modern therapy to advanced non small cell lung cancer2017 | Faculty of Medicine in Pilsen
- Management of the metastatic renal cancer2023 | Faculty of Medicine in Hradec Králové
- Chronic myeloid leukaemia - standardization of BCR-ABL1 transcript level monitoring in the Czech Republic2016 | Publication without faculty affiliation
- Antiangiogenic therapy of lung cancer2018 | Second Faculty of Medicine
- Bosutinib v léčbě chronické myeloidní leukemie2019 | Faculty of Medicine in Hradec Králové
- Pazopanib in the treatment of renal cell carcinoma2012 | Second Faculty of Medicine
- Lorlatinib in the treatment of non‑small cell lung cancer2020 | Publication without faculty affiliation
- Endocrine complications of modern cancer therapy2016 | Faculty of Medicine in Hradec Králové